Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Modi, S., Saura, C., Yamashita, T., Park, Y.H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., Sohn, J., Denduluri, N., Perrin, C., Aogi, K., Tokunaga, E., Im, S.-A., Lee, K.S., Hurvitz, S.A., Cortes, J., Lee, C., Chen, S., Zhang, L., Shahidi, J., Yver, A., Krop, I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458671/
https://ncbi.nlm.nih.gov/pubmed/31825192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1914510
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller